Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years old or older.~2. Histologically or cytologically confirmed diagnosis of a solid tumor (RCC, HCC, or colorectal cancer).~3. Participants are planning to initiate treatment with either sorafenib or regorafenib as a single chemotherapeutic agent~4. Able to swallow and retain oral medication and does not have any clinically relevant, active gastrointestinal disease or other condition that may significantly alter absorption, distribution, metabolism, or excretion of drugs.~5. Be able to provide written informed consent.~Exclusion Criteria~1. Patients who are or will be receiving other chemotherapeutic or molecularly targeted agents in addition to sorafenib or regorafenib~2. Concurrent moderate or severe chronic inflammatory skin condition (eczema, psoriasis)~3. Concurrent blistering skin disorder of any severity (such as pemphigus, bullous pemphigoid)~4. Connective tissue disorders with skin involvement (systemic lupus erythematosus, scleroderma, dermatomyositis, etc.)~5. Patients manifesting an allergic skin reaction (such as urticaria) or skin reaction as a complication of prior chemotherapy~6. Patients with skin lesions of infectious or non-infectious cause, precluding skin biopsy~7. Patients not willing to undergo skin biopsy~8. Patients who are pregnant or planning to become pregnant during their participation in the study.~9. Chemotherapy, targeted therapy, or biological therapy within two weeks of start of treatment.~10. Ability to give informed consent is compromised by cognitive and/or decisional impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).